Comparison between indacaterol and tiotropium on respiratory function and exercise tolerance in COPD patients

Comparison between indacaterol and tiotropium on respiratory function and exercise tolerance in COPD patients - Efficacy of indacaterol vs. tiotropium in COPD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008268

Enrollment

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Group A tiotropium18microgram(more than 2 months)indacaterol 150microgram(2 months)tiotropium18microgram(2 months) Group B tiotropium18microgram(more than 2 months)tiotropium18microgram(2 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD outpatients who consent to this clinical research

Exclusion criteria

Exclusion criteria: patients who had admitted due to COPD exacerbation in 6 weeks patients who had bronchial infection in 6 weeks patients who had asthma in past pregnant women and women who may be in pregnancy patients who have severe complications as heart diseases, liver disfunction and renal disfunction patients who doctors regarded unsuitable for this trial patients who had allergy for the ingredients of these medicine

Design outcomes

Primary

Measure	Time frame
Respiratory function and 6 minutes walk test	—

Countries

Japan

Contacts

Public ContactTomoko Suzuki

Saitama Medical University Hospital Respiratory Medicine

049-276-1319

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026